News

TSO3 ANNOUNCES FILING OF PRELIMINARY SHORT FORM PROSPECTUS

Québec City, February 15, 2013 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 7,000,000 common shares (the “Common Shares”) at the price of CDN $1.00 per Common Share (the “Issue Price”) for aggregate gross proceeds to TSO3 of CDN $7,000,000 (“the Offering”).

Read more

News

TSO3 announces cdn $ 7,000,000 offering on a bought deal basis

Québec City, February 13, 2013 – TSO3 Inc. (the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, is pleased to announce today that it has entered into a bought deal agreement with a syndicate of underwriters led by Desjardins Capital Markets (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase 7,000,000 common shares (the “Common Shares”) in the capital of TSO3 at the price of CDN $1.00 per Common Share (the “Issue Price”) for aggregate gross proceeds to TSO3 of CDN $7,000,000 (the “Offering”). Under the terms of the agreement, the Company will request an advance income tax ruling from Agence du revenu du Québec confirming that the Common Shares constitute qualifying shares for the Québec Stock Savings Plan II, in accordance with applicable legislation. The Offering is expected to close on or about March 4, 2013 and is subject to customary conditions and regulatory approvals.

Read more

News

TSO3 Files New and Simplified Submission to the US Regulatory Agency – Company seeking United States clearance for its STERIZONE® 125L+ Sterilizer

Quebec City, January 28, 2013 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”) an innovator in sterilization technology for medical devices in healthcare settings, today announced that consistent with its December 14 2012 disclosure, the Company has filed a new and simplified submission with the US regulatory agency seeking commercial clearance of its STERIZONE® 125L+ Sterilizer in that market.

Read more